SciClone completes going private deal

A consortium of investors led by GL Capital and including Bank of China, CDH, Ascendent Capital Partners and Boying completed its acquisition of SciClone Pharmaceuticals Inc. for $11.18 per share in cash. The deal valued SciClone at $583.5 million based on 52.2 million shares outstanding as of June 30. SciClone's Zadaxin thymalfasin, a synthetic thymosin alpha-1, is approved as an immune system enhancer and to treat HBV and HCV infections and certain cancers (see BioCentury, June 9).

SciClone is now a subsidiary of Silver Biotech Investment Ltd. (Cayman Islands)...